Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)

CrowdKnowsBest (< 20) Submitted: 2/6/2012 8:19:13 PM : Start Price: $3.24 THLD Score: -3.85

Getting in late, hope the stock continues its momentum. February and March are supposed to be big for biotech with FDA announcements.

STAINEDGLASSER (76.61) Submitted: 2/6/2012 1:26:49 PM : Start Price: $3.63 THLD Score: -14.04

They have numerous cancer drugs in the works that appear to be doing well in clinical trials. They recently inked a deal with Merck in Germany to commercialize one of their drugs, which is also an indication that they are doing well.

hiddenflem (81.11) Submitted: 2/3/2012 2:01:56 PM : Start Price: $2.20 THLD Score: +41.55

Factor in the money they got from Merck today along with the presumption that the first milestone will be met (otherwise why would Merck be partnering with them) and this looks cheap. very cheap.

JuanPeter (61.34) Submitted: 1/18/2012 5:27:11 PM : Start Price: $1.55 THLD Score: -98.90

If Threshold had the cure for pancreatic cancer, it wouldn't be trading at a buck and a half and have a $74M market cap. TH-302 is a topoisomerase II inhibitor that demonstrated good data in previous trials...with just one little detail that characterizes many p2 cancer trials: it lacked a comparator arm. Therefore, the debate goes as usual: the company touts its drug as better than historical data and then, to everybody's surprise, the p3 fails because patients in the comparator arm are living longer than expected. The phase II trial testing TH-302 plus gemcitabine is expected to read out in mid to late February.

Threshold's history of failed drugs and shareholder dilution doesn't help much either. Moreover, other topoisomerase II inhibitors have failed previous trials in pancreatic cancer so...we have it all set up!

portefeuille (99.81) Submitted: 12/16/2011 12:23:05 AM : Start Price: $1.35 THLD Score: +123.43

There are currently 4500 THLD shares in my "fund" with break-even of around 0.04 USD. http://caps.fool.com/Blogs/fund-trades/678775.

Momentum21 (96.66) Submitted: 5/19/2011 1:59:18 PM : Start Price: $1.86 THLD Score: +67.94

Looking for a bounce into ASCO. We are past yet another round of dilution and there has been some notable insider and institutional buying of late. Highly speculative but not much more then some of my other holdings. M21 in at 1.87...boo yah

topsecret10 (23.96) Submitted: 4/1/2011 11:56:58 AM : Start Price: $1.60 THLD Score: +94.50

Latest direct offering netted company 30 million dollars. Insiders and Institutions have purchased over 5 million shares since early March. Stock Is now about 40 cents under their average buying prices. I love these little biotechs,and I like the drug discovery platform that this company Is using. Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.

SorrySam (72.47) Submitted: 3/19/2011 12:25:26 AM : Start Price: $1.69 THLD Score: +80.74

insider buying

polvo23 (< 20) Submitted: 2/11/2007 7:51:58 PM : Start Price: $3.31 THLD Score: -4.82

phase 3...did all the research

epocrates (< 20) Submitted: 2/2/2007 10:47:48 AM : Start Price: $3.48 THLD Score: +8.83

Pancreatic cancer is hard to show survival. Refractory pancreatic cancer is impossible to survival.

Rhondalo (< 20) Submitted: 12/29/2006 11:45:56 AM : Start Price: $3.72 THLD Score: -16.53

Trials look positive for pancreatic cancer and they may resume clinical research for prostate cancer.